The stock of Jazz Pharmaceuticals plc (JAZZ) has seen a 5.03% increase in the past week, with a 4.08% gain in the past month, and a 14.53% flourish in the past quarter. The volatility ratio for the week is 2.30%, and the volatility levels for the past 30 days are at 3.08% for JAZZ. The simple moving average for the last 20 days is 1.46% for JAZZ stock, with a simple moving average of 19.93% for the last 200 days.
Is It Worth Investing in Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Right Now?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has a price-to-earnings ratio of 16.11x that is above its average ratio. Additionally, the 36-month beta value for JAZZ is 0.37. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 9 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAZZ is 57.97M and currently, short sellers hold a 7.53% ratio of that float. The average trading volume of JAZZ on March 19, 2025 was 760.78K shares.
JAZZ) stock’s latest price update
The stock price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has surged by 1.01 when compared to previous closing price of 139.51, but the company has seen a 5.03% gain in its stock price over the last five trading sessions. zacks.com reported 2025-03-19 that The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts’ Opinion of JAZZ
Many brokerage firms have already submitted their reports for JAZZ stocks, with UBS repeating the rating for JAZZ by listing it as a “Buy.” The predicted price for JAZZ in the upcoming period, according to UBS is $179 based on the research report published on March 07, 2025 of the current year 2025.
Wells Fargo gave a rating of “Overweight” to JAZZ, setting the target price at $170 in the report published on February 13th of the current year.
JAZZ Trading at 8.05% from the 50-Day Moving Average
After a stumble in the market that brought JAZZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.83% of loss for the given period.
Volatility was left at 3.08%, however, over the last 30 days, the volatility rate increased by 2.30%, as shares surge +4.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.90% upper at present.
During the last 5 trading sessions, JAZZ rose by +5.05%, which changed the moving average for the period of 200-days by +33.63% in comparison to the 20-day moving average, which settled at $138.89. In addition, Jazz Pharmaceuticals plc saw 14.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JAZZ starting from Iannone Robert, who sale 2,403 shares at the price of $138.41 back on Mar 10 ’25. After this action, Iannone Robert now owns 79,621 shares of Jazz Pharmaceuticals plc, valued at $332,605 using the latest closing price.
Carr Patricia, the SVP, Chief Accounting Officer of Jazz Pharmaceuticals plc, sale 1,140 shares at $137.81 during a trade that took place back on Mar 10 ’25, which means that Carr Patricia is holding 7,012 shares at $157,103 based on the most recent closing price.
Stock Fundamentals for JAZZ
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.85 for the gross margin
The net margin for Jazz Pharmaceuticals plc stands at 0.14. The total capital return value is set at 0.07. Equity return is now at value 14.31, with 4.79 for asset returns.
Based on Jazz Pharmaceuticals plc (JAZZ), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 19.96. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 3.05.
Currently, EBITDA for the company is 716.63 million with net debt to EBITDA at -1.88. When we switch over and look at the enterprise to sales, we see a ratio of 1.52. The receivables turnover for the company is 5.68for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.46.
Conclusion
In conclusion, Jazz Pharmaceuticals plc (JAZZ) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
